Effect of Bacteroides Fragilis Grown in the Presence of Clindamycin, Metronidazole and Fusidic Acid on Opsonization and Killing of Escherichia Coli

Overview

Journal Eur J Clin Microbiol

Specialty Microbiology

Date 1986 Jun 1

PMID 3527702

Authors

F Namavar

J A Kaan

W A Vel

M Bal

A D Kester

D M MACLAREN

Affiliations

Soon will be listed here.

Abstract

Bactericidal action of human polymorphonuclear leucocytes on Escherichia coli in the presence of Bacteroides fragilis grown in subinhibitory concentrations of clindamycin, metronidazole and fusidic acid was studied. Bacteroides fragilis grown in the absence of drugs significantly inhibited the killing of Escherichia coli. Bacteroides fragilis grown in the presence of the drugs had a reduced inhibitory effect on the killing of Escherichia coli but this reduction was only significant for Bacteroides fragilis grown in 1/2 MIC of clindamycin. The phagocytosis of Bacteroides fragilis grown with and without clindamycin, as measured by killing, was the same. Complement consumption of Bacteroides fragilis grown with and without clindamycin did not differ. Clindamycin-treated Bacteroides fragilis fixed C3 to a significantly lower degree than did untreated bacteria. The chemiluminescence of Escherichia coli opsonized with serum preincubated with clindamycin-treated Bacteroides fragilis was significantly higher than with serum preincubated with untreated bacteria. These results suggested that in killing experiments of mixed Escherichia coli and Bacteroides fragilis, the mechanism underlying the reduced inhibitory capacity of clindamycin-exposed Bacteroides fragilis is related to greater availability of C3 in serum for opsonization of Escherichia coli.

References

Gemmell C, Peterson P, Schmeling D, Mathews J, Quie P . Antibiotic-induced modification of Bacteroides fragilis and its susceptibility to phagocytosis by human polymorphonuclear leukocytes. Eur J Clin Microbiol. 1983; 2(4):327-34. DOI: 10.1007/BF02019462. View

MACLAREN D, Namavar F, Vel W, Kaan J . Pathogenic synergy: mixed intra-abdominal infections. Antonie Van Leeuwenhoek. 1984; 50(5-6):775-87. DOI: 10.1007/BF02386240. View

Connolly J, Mclean C, TABAQCHALI S . The effect of capsular polysaccharide and lipopolysaccharide of Bacteroides fragilis on polymorph function and serum killing. J Med Microbiol. 1984; 17(3):259-71. DOI: 10.1099/00222615-17-3-259. View

Hand W, Johnson J . Influence of bacterial-antibiotic interactions on subsequent antimicrobial activity of alveolar macrophages. J Infect Dis. 1984; 149(2):271-6. DOI: 10.1093/infdis/149.2.271. View

Onderdonk A, Louie T, Tally F, Bartlett J . Activity of metronidazole against Escherichia coli in experimental intra-abdominal sepsis. J Antimicrob Chemother. 1979; 5(2):201-10. DOI: 10.1093/jac/5.2.201. View

Milatovic D, Braveny I, Verhoef J . Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother. 1983; 24(3):413-7. PMC: 185334. DOI: 10.1128/AAC.24.3.413. View

Shah H, Williams R, BOWDEN G, Hardie J . Comparison of the biochemical properties of Bacteroides melaninogenicus from human dental plaque and other sites. J Appl Bacteriol. 1976; 41(3):473-95. DOI: 10.1111/j.1365-2672.1976.tb00660.x. View

Gemmell C, Peterson P, Schmeling D, Kim Y, Mathews J, Wannamaker L . Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest. 1981; 67(5):1249-56. PMC: 370690. DOI: 10.1172/jci110152. View

Ingham H, Sisson P, Middleton R, Narang H, Codd A, Selkon J . Phagocytosis and killing of bacteria in aerobic and anaerobic conditions. J Med Microbiol. 1981; 14(4):391-9. DOI: 10.1099/00222615-14-4-391. View

10.

Vel W, Namavar F, Pubben A, MACLAREN D . Killing of Escherichia coli by human polymorphonuclear leucocytes in the presence of Bacteroides fragilis. J Clin Pathol. 1985; 38(1):86-91. PMC: 499078. DOI: 10.1136/jcp.38.1.86. View

11.

Mandell L . Effects of antimicrobial and antineoplastic drugs on the phagocytic and microbicidal function of the polymorphonuclear leukocyte. Rev Infect Dis. 1982; 4(3):683-97. DOI: 10.1093/clinids/4.3.683. View

12.

Namavar F, Sparrius M, Vel W, MACLAREN D . Pathogenic synergy between Escherichia coli and Bacteroides fragilis: studies in an experimental mouse model. J Med Microbiol. 1985; 19(3):325-31. DOI: 10.1099/00222615-19-3-325. View

13.

Jones G, Gemmell C . Impairment by Bacteroides species of opsonisation and phagocytosis of enterobacteria. J Med Microbiol. 1982; 15(3):351-61. DOI: 10.1099/00222615-15-3-351. View

14.

Shapiro M, Sacks T . A decisive period in cefoxitin prophylaxis of experimental synergistic wound infection produced by Bacteroides fragilis and Escherichia coli. Isr J Med Sci. 1982; 18(8):863-5. View

15.

Steinberg T, Hand W . Effects of phagocytosis on antibiotic and nucleoside uptake by human polymorphonuclear leukocytes. J Infect Dis. 1984; 149(3):397-403. DOI: 10.1093/infdis/149.3.397. View

16.

Gemmell C, Spear T, Peterson P . Morphological changes in bacteroides fragilis and klebsiella pneumoniae attributable to growth in the presence of various antibiotics. Eur J Clin Microbiol. 1983; 2(3):217-21. DOI: 10.1007/BF02029520. View

17.

Wade B, Kasper D, Mandell G . Interactions of Bacteroides fragilis and phagocytes: studies with whole organisms, purified capsular polysaccharide and clindamycin-treated bacteria. J Antimicrob Chemother. 1983; 12 Suppl C:51-62. DOI: 10.1093/jac/12.suppl_c.51. View

18.

Ingham H, Sisson P, Tharagonnet D, Selkon J, Codd A . Inhibition of phagocytosis in vitro by obligate anaerobes. Lancet. 1977; 2(8051):1252-4. DOI: 10.1016/s0140-6736(77)92662-9. View

19.

Prokesch R, Hand W . Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1982; 21(3):373-80. PMC: 181898. DOI: 10.1128/AAC.21.3.373. View

20.

Namavar F, Verweij A, Bal M, van Steenbergen T, de Graaff J, MACLAREN D . Effect of anaerobic bacteria on killing of Proteus mirabilis by human polymorphonuclear leukocytes. Infect Immun. 1983; 40(3):930-5. PMC: 348141. DOI: 10.1128/iai.40.3.930-935.1983. View